# A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

> **NCT06032546** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 163 (actual)

## Conditions studied

- Human Immuno-deficiency Virus (HIV) Disease

## Interventions

- **DRUG:** Budigalimab
- **DRUG:** Placebo for Budigalimab
- **DRUG:** ABBV-382
- **DRUG:** Placebo for ABBV-382
- **DRUG:** Budigalimab

## Key facts

- **NCT ID:** NCT06032546
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-12
- **Primary completion:** 2025-09-22
- **Final completion:** 2025-09-22
- **Target enrollment:** 163 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06032546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06032546, "A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06032546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*